HRTX 10-Q: SEC filing

Heron Therapeutics

Filed with the SEC on Nov 9, 2026 · accession 0001193125-26-452759

HRTX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. Heron Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing financial results, including revenue from its acute care products (APONVIE, ZYNRELEF, CINVANTI, SUSTOL), and a subsequent event involving an asset purchase agreement with CorMedix Inc. for… The stock moved +26.5% by the first close after the filing.

Summary of the filing

Heron Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing financial results, including revenue from its acute care products (APONVIE, ZYNRELEF, CINVANTI, SUSTOL), and a subsequent event involving an asset purchase agreement with CorMedix Inc. for ZYNRELEF dated November 8, 2026.

For details, click here →How to read a 10-Q →

Key details

FilerHeron Therapeutics, Inc.

Counterparty to subsequent event asset purchase agreement for zynrelefCorMedix Inc.

Lender under loan agreementHercules Capital, Inc.

Holder of 2031 senior unsecured convertible notesRubric Capital Management LP

How HRTX stock reacted

Close before

$0.29

Nov 6, 2026

First close after

+26.48%

$0.37

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for HRTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for HRTX?

Click here

Frequently asked questions

What did HRTX file with the SEC on Nov 9, 2026?

HRTX filed a 10-Q (SEC filing). Heron Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing financial results, including revenue from its acute care products (APONVIE, ZYNRELEF, CINVANTI, SUSTOL), and a subsequent event involving an asset purchase agreement with CorMedix Inc. for ZYNRELEF dated November 8, 2026.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did HRTX stock react to this filing?

HRTX closed at $0.29 before the filing and $0.37 on Nov 9, 2026 (+26.48%).

Other HRTX SEC filings

Get alerts when HRTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

HRTX overview HRTX analysis HRTX news Latest SEC filings